Genesis Lifestyle Medicine Semaglutide Review

Genesis Lifestyle Medicine is one of the larger multi-state operators in this comparison, combining weight loss with hormone therapy and aesthetics. Our research (August 8, 2026) found a broad national footprint and modest published detail.

Scale and Scope

"Genesis Lifestyle Medicine is a world-class weight loss, hormone therapy, and aesthetics center with locations across the US. Our services combined with a multi-discipline approach help our patients not only reach their goals, but also provides them with a much healthier and happier lifestyle."

A multi-state network means in-person access across many markets, which is a real advantage over both single-location practices and shipped-vial telehealth. The multi-disciplinary framing — weight loss, hormones and aesthetics under one roof — suits patients who want those services coordinated rather than fragmented. It also means, as with any chain of this type, that GLP-1 care sits on a menu alongside cosmetic services. That is not a criticism in itself, but it is worth knowing that the practice's revenue does not depend solely on medical weight management.

Labs Are Part of the Offering

The practice lists insulin and thyroid labs among its services alongside compounded semaglutide and compounded tirzepatide. Insulin and thyroid testing are both clinically relevant to weight management — thyroid dysfunction is a genuine and treatable cause of weight gain that should be excluded, and insulin markers speak to the metabolic picture. Offering them alongside GLP-1s indicates a practice looking past the prescription.

The Framing Is Restrained

"Weight loss can be a frustrating challenge, with negative impacts on overall health and body image. GLP-1 medication is a convenient solution that aids appetite suppression and promotes significant weight loss over time."

"Over time" is the operative phrase, and it is accurate — the trial results accrued over 68 to 72 weeks. A practice that says "over time" rather than promising rapid transformation is setting expectations correctly, and it stands in contrast to the operators we have documented advertising dramatic short-term figures.

Compounded, and Not Much Else Disclosed

The offering is explicitly compounded semaglutide and compounded tirzepatide — the practice says so plainly rather than marketing generic "GLP-1," which is to its credit. But that is where the disclosure stops. No pricing. No named compounding pharmacy and no 503A or 503B status. No third-party testing or beyond-use dating. No published BMI or eligibility criteria, dosing protocol or monitoring schedule. And the specific locations were not enumerated in the material we reviewed, so patients must use the location finder to establish whether the practice reaches them. Given manufacturer-direct pricing now available through LillyDirect and NovoCare, anyone offered compounded medication here should ask what it costs and compare.